Astellas calls time on ex-Dynogen US facility as it tidies R&D network
This article was originally published in Scrip
Astellas is to close down a small research subsidiary in the US by the end of this year, as it looks to control costs and rationalise its corporate R&D effort.
You may also be interested in...
In this week's podcast edition of Five Must-Know Things: the biggest drug launches expected in 2024; Roche’s Pharma CEO talks about growth momentum; 10 pivotal studies to look out for this year; the obesity market now and in future; and what does 2024 hold for transformative technology in biopharma.
In this week's podcast edition of Five Must-Know Things: Bayer’s pipeline refresh; J&J’s selective pharma M&A approach; silver lining for Gilead’s Trodelvy miss?; paying for obesity drugs; and the story behind Vertex and CRISPR’s gene therapy breakthrough.
In this week's podcast edition of Five Must-Know Things: major takeaways and highlights from the JP Morgan meeting; J&J bets on ADCs with Ambrx buy; the Indian GLP-1 battleground; and Scrip asks what 2024 holds for business strategy and leadership.